159938 医药
已收盘 04-23 15:00:00
资讯
新帖
简况
大型医药股表现活跃，资金连续4个交易日流入医药ETF易方达（512010）
证券之星 · 04-23 19:49
大型医药股表现活跃，资金连续4个交易日流入医药ETF易方达（512010）
中恒集团（600252）披露广西力合中恒医药投资合伙企业完成清算注销公告，4月23日股价下跌0.8%
证券之星 · 04-23 17:55
中恒集团（600252）披露广西力合中恒医药投资合伙企业完成清算注销公告，4月23日股价下跌0.8%
和誉-B(02256)：和誉医药于2026年AACR年会展示六项研究进展，聚焦pan-KRAS、四代EGFR及合成致死等创新路线
智通财经 · 04-23 08:05
和誉-B(02256)：和誉医药于2026年AACR年会展示六项研究进展，聚焦pan-KRAS、四代EGFR及合成致死等创新路线
创胜集团医药-B(06628)公布其新型LIV1 ADC TST013在前列腺癌及 ER阳性╱HER2阴性乳腺癌PDX模型中显示出强大的抗肿瘤活性的新数据
智通财经 · 04-23 07:00
创胜集团医药-B(06628)公布其新型LIV1 ADC TST013在前列腺癌及 ER阳性╱HER2阴性乳腺癌PDX模型中显示出强大的抗肿瘤活性的新数据
汇添富基金张韡旗下汇添富创新医药一季报最新持仓，重仓科伦博泰生物
证券之星 · 04-22 19:09
汇添富基金张韡旗下汇添富创新医药一季报最新持仓，重仓科伦博泰生物
刘盟盟2026年一季度表现，天弘医药创新A基金季度涨幅0.78%
证券之星 · 04-22 18:06
刘盟盟2026年一季度表现，天弘医药创新A基金季度涨幅0.78%
瑞医药一季度归母净利润22.8亿元，同比增长21.8%
财中社 · 04-22 17:44
瑞医药一季度归母净利润22.8亿元，同比增长21.8%
4月22日悦康药业涨5.49%，富国医药创新股票A基金重仓该股
证券之星 · 04-22 16:30
4月22日悦康药业涨5.49%，富国医药创新股票A基金重仓该股
劲方医药-B午前涨超4% 公司公布泛RAS抑制剂GFH276临床前研究数据
新浪港股 · 04-22 11:54
劲方医药-B午前涨超4% 公司公布泛RAS抑制剂GFH276临床前研究数据
长春高新2025年净利润同比下降94%；翰森制药公布抗失眠新药临床数据｜医药早参
每日经济新闻 · 04-22 07:02
长春高新2025年净利润同比下降94%；翰森制药公布抗失眠新药临床数据｜医药早参
中国生物制药(01177)：礼新医药于AACR 2026公布两款ADC最新研究数据
智通财经 · 04-22 06:16
中国生物制药(01177)：礼新医药于AACR 2026公布两款ADC最新研究数据
诺禾致源：4月14日召开业绩说明会，国联民生医药、中金医药参与
证券之星 · 04-21 18:52
诺禾致源：4月14日召开业绩说明会，国联民生医药、中金医药参与
天保基建：天津天保医药科技发展有限公司与您提及的公司无业务合作关系
证券之星 · 04-21 16:09
天保基建：天津天保医药科技发展有限公司与您提及的公司无业务合作关系
金笑非2026年一季度表现，鹏华创新医药混合A基金季度涨幅10.29%
证券之星 · 04-21 09:34
金笑非2026年一季度表现，鹏华创新医药混合A基金季度涨幅10.29%
中国生物制药(01177)：礼新医药于AACR 2026公布MK-2010/LM-299初步临床数据
智通财经 · 04-19
中国生物制药(01177)：礼新医药于AACR 2026公布MK-2010/LM-299初步临床数据
批发毛利见底，服务重构破局：万亿医药流通靠零售“回血”？
21世纪经济报道 · 04-17
批发毛利见底，服务重构破局：万亿医药流通靠零售“回血”？
宝莫股份：目前公司产品暂未应用于医药领域
证券之星 · 04-17
宝莫股份：目前公司产品暂未应用于医药领域
同源康医药(02410)自主研发TY-3002单药展现卓越减重疗效，引领下一代口服GLP-1R小分子创新
智通财经 · 04-16
同源康医药(02410)自主研发TY-3002单药展现卓越减重疗效，引领下一代口服GLP-1R小分子创新
4月16日爱迪特涨10.33%，银河医药混合A基金重仓该股
证券之星 · 04-16
4月16日爱迪特涨10.33%，银河医药混合A基金重仓该股
北京将加快中关村生命科学园三期建设 推动AI+医药、脑机接口等产业发展
中国新闻网 · 04-15
北京将加快中关村生命科学园三期建设 推动AI+医药、脑机接口等产业发展
公司概况
公司名称：
--
所属市场：
上市日期：
--
主营业务：
发行价格：
--
{"stockData":{"symbol":"159938","market":"SZ","secType":"STK","nameCN":"医药","latestPrice":0.641,"timestamp":1776927825000,"preClose":0.642,"halted":0,"volume":55656700,"delay":0,"changeRate":-0.0016,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盘","change":-0.001,"latestTime":"04-23 15:00:00","open":0.642,"high":0.646,"low":0.637,"amount":35685900,"amplitude":0.014,"askPrice":0.641,"askSize":872,"bidPrice":0.64,"bidSize":973,"shortable":0,"etf":1,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1776994200000},"marketStatusCode":5,"adr":0,"adjPreClose":0.642,"symbolType":"fund","openAndCloseTimeList":[[1776907800000,1776915000000],[1776920400000,1776927600000]],"highLimit":0.706,"lowLimit":0.578,"ibTradeSell":false,"ibTradeBuySell":true,"isCdr":false,"pbRate":0,"committee":0.124069,"marketValue":0,"turnoverRate":0,"status":1,"floatMarketCap":0},"requestUrl":"/m/hq/s/159938/wiki","defaultTab":"wiki","newsList":[{"id":"2629583647","title":"大型医药股表现活跃，资金连续4个交易日流入医药ETF易方达（512010）","url":"https://stock-news.laohu8.com/highlight/detail?id=2629583647","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629583647?lang=zh_cn&edition=full","pubTime":"2026-04-23 19:49","pubTimestamp":1776944992,"startTime":"0","endTime":"0","summary":"4月23日，市场多数板块回调，大型医药股表现活跃，爱尔眼科涨超5%，爱美客、新产业涨超2%，恒瑞医药、新和成涨超1%，指数层面，沪深300医药卫生指数上涨0.6%，中证创新药产业指数下跌1.1%，中证生物科技主题指数下跌1.3%，中证港股通医药卫生综合指数下跌3.7%，恒生港股通创新药指数下跌4.9%。Wind数据显示，截至昨日，跟踪沪深300医药卫生指数的医药ETF易方达(512010，联接基金A/C：001344/007883)连续4个交易日获资金净流入，合计超4亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/SS2026042300056163.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","512010","BK1161","09939","159938","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629188247","title":"中恒集团（600252）披露广西力合中恒医药投资合伙企业完成清算注销公告，4月23日股价下跌0.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629188247","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629188247?lang=zh_cn&edition=full","pubTime":"2026-04-23 17:55","pubTimestamp":1776938129,"startTime":"0","endTime":"0","summary":"截至2026年4月23日收盘，中恒集团报收于2.48元，较前一交易日下跌0.8%，最新总市值为78.97亿元。该股当日开盘2.51元，最高2.51元，最低2.46元，成交额达5628.1万元，换手率为0.71%。公告显示，公司于2021年6月决定参与投资设立广西力合中恒医药投资合伙企业，认缴出资29,700.00万元，实缴出资2,000.00万元。由于基金未开展项目投资，经全体合伙人同意，公司于2025年12月启动清算注销程序。本次清算注销不会对公司财务状况和日常经营产生实质性影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042300049472.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK0015","BK0028","BK1515","159938","600252","BK0188","BK0012","BK0077","BK0239","BK1161","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629315074","title":"和誉-B(02256)：和誉医药于2026年AACR年会展示六项研究进展，聚焦pan-KRAS、四代EGFR及合成致死等创新路线","url":"https://stock-news.laohu8.com/highlight/detail?id=2629315074","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629315074?lang=zh_cn&edition=full","pubTime":"2026-04-23 08:05","pubTimestamp":1776902727,"startTime":"0","endTime":"0","summary":"研究结果表明，ABSK211可通过多机制协同显著增强抗肿瘤效果，为后续联合多种治疗策略进入临床开发提供了支持。研究结果支持进一步开发ABK-EGFR-1作为下一代靶向治疗药物，用于 EGFR耐药肿瘤，尤其适用于伴有脑转移的患者。和誉医药在本次2026年AACR年会上集中展示了多个产品管线的最新临床前研究和转化医学研究进展，体现了公司在早期药物发现与开发方面的强大能力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432385.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","IE00BPRC5H50.USD","IE00B543WZ88.USD","159938","02256","IE00B5MMRT66.SGD","LU2476274720.SGD","LU2778985437.USD","BK1161","LU2488822045.USD","LU2476274308.USD","09939","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629079406","title":"创胜集团医药-B(06628)公布其新型LIV1 ADC TST013在前列腺癌及 ER阳性╱HER2阴性乳腺癌PDX模型中显示出强大的抗肿瘤活性的新数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2629079406","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629079406?lang=zh_cn&edition=full","pubTime":"2026-04-23 07:00","pubTimestamp":1776898849,"startTime":"0","endTime":"0","summary":"智通财经APP讯，创胜集团医药-B 公布，于2026年AACR年会上发表强调其自主研发的LIV1抗体偶联药物的临床前数据。对于LIV1表达的前列腺癌PDX模型，ADC-2在给药两剂后显示出有限的肿瘤生长抑制。总体而言，该等数据证明创胜医药的LIV1 ADC-2及ADC-3项目在ER阳性╱Her2 阴性乳腺癌以及前列腺癌的PDX模型中作为单药疗法显示出强大的抗肿瘤活性。该等结果支持进一步研究创胜医药的LIV1 ADC在LIV1阳性实体瘤中的应用。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432372.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","PDX","BK1515","06628","BK4231","BK4080","ADC","BK1161","09939","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629048496","title":"汇添富基金张韡旗下汇添富创新医药一季报最新持仓，重仓科伦博泰生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2629048496","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629048496?lang=zh_cn&edition=full","pubTime":"2026-04-22 19:09","pubTimestamp":1776856147,"startTime":"0","endTime":"0","summary":"证券之星消息，4月22日汇添富基金旗下张韡管理的汇添富创新医药主题混合型基金公布一季报，近1年净值增长率24.35%。与上一季度相比，该基金前十大重仓股新增信立泰，荣昌生物；其中科伦博泰生物持仓占比9.71%，为该基金第一大重仓股；热景生物，新诺威等退出前十大重仓股；详细数据如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042200046509.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","LU0196878994.USD","BK1515","BK1161","06990","09939","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629012582","title":"刘盟盟2026年一季度表现，天弘医药创新A基金季度涨幅0.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629012582","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629012582?lang=zh_cn&edition=full","pubTime":"2026-04-22 18:06","pubTimestamp":1776852393,"startTime":"0","endTime":"0","summary":"证券之星消息，截止2026年一季度末，基金经理刘盟盟旗下共管理8只基金，本季度表现最佳的为天弘医药创新A，季度净值涨0.78%。刘盟盟在担任天弘医疗健康混合A基金经理的任职期间累计任职回报57.41%，平均年化收益率为6.59%。持有期间的估算收益率为317.89%，持有期间山东药玻在2018年到2020年的年报归属净利润增幅达57.57%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042200041949.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","09939","159938","BK1574","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629149760","title":"瑞医药一季度归母净利润22.8亿元，同比增长21.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629149760","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629149760?lang=zh_cn&edition=full","pubTime":"2026-04-22 17:44","pubTimestamp":1776851040,"startTime":"0","endTime":"0","summary":"4月22日，恒瑞医药(600276)公布2026年一季报，公司营业收入81.41亿元，同比增长12.98%；归母净利润为22.8亿元，同比上升21.8%；扣非归母净利润为21.7亿元，同比上升16.6%；经营现金流净额为7.86亿元，同比增长41.7%；EPS(全面摊薄)为0.3439元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604223714180229.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09939","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629015184","title":"4月22日悦康药业涨5.49%，富国医药创新股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2629015184","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629015184?lang=zh_cn&edition=full","pubTime":"2026-04-22 16:30","pubTimestamp":1776846615,"startTime":"0","endTime":"0","summary":"证券之星消息，4月22日悦康药业涨5.49%，收盘报19.8元，换手率3.02%，成交量13.59万手，成交额2.64亿元。重仓悦康药业的公募基金请见下表：根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共7家，其中持有数量最多的公募基金为富国基金的富国医药创新股票A。富国医药创新股票A目前规模为9.48亿元，最新净值1.717，较上一交易日下跌1.05%，近一年上涨33.73%。该公募基金现任基金经理为赵伟 王超。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042200037757.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK1515","BK1574","BK0239","09939","159938","688658"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629096870","title":"劲方医药-B午前涨超4% 公司公布泛RAS抑制剂GFH276临床前研究数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2629096870","media":"新浪港股","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629096870?lang=zh_cn&edition=full","pubTime":"2026-04-22 11:54","pubTimestamp":1776830040,"startTime":"0","endTime":"0","summary":" 劲方医药-B盘中涨近6%，截至发稿，股价上涨4.41%，现报45.94港元，成交额2121.73万港元。 劲方医药宣布，公司自主开发的口服Pan RAS抑制剂GFH276临床前研究数据，于当地时间4月21日登陆美国癌症研究协会年会壁报展示。 此外，GFH276与西妥昔单抗、化疗药物或PD-1单抗分别联用的动物实验中，可展现显著的抑瘤增效及无瘤生存期延长。据悉，GFH276为全球第三款进入临床试验的Pan RAS抑制剂，并在临床早期数据中显示契合临床前疗效及安全性的初步结果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-04-22/doc-inhvixkk6243796.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09939","159938","02595","BK1161","BK1574","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629069622","title":"长春高新2025年净利润同比下降94%；翰森制药公布抗失眠新药临床数据｜医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2629069622","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629069622?lang=zh_cn&edition=full","pubTime":"2026-04-22 07:02","pubTimestamp":1776812539,"startTime":"0","endTime":"0","summary":"｜2026年4月22日星期三｜NO.1长春高新2025年净利润1.55亿元，同比下降94%4月21日，长春高新披露2025年年度报告。2025年，公司实现营业收入120.83亿元，较上年同期降低10.27%；归属于上市公司股东的净利润为1.55亿元，较上年同期降低94%。公司拟向全体股东每10股派发现金红利1.60元(含税)，送红股0股，不以公积金转增股本。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604223713055256.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604223713055256.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09939","03692","000661","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629906669","title":"中国生物制药(01177)：礼新医药于AACR 2026公布两款ADC最新研究数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2629906669","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629906669?lang=zh_cn&edition=full","pubTime":"2026-04-22 06:16","pubTimestamp":1776809789,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药 公布，该集团全资附属公司礼新医药科技(上海)有限公司自主研发的两款新一代抗体偶联药物 LM-364 “Nectin-4TME ADC”及LM-338 “STn ADC”，于2026年美国癌症研究协会年会公布最新研究数据。LM-364是礼新医药依托自主开发的肿瘤微环境平台开发的新一代Nectin-4TME ADC。目前，LM-364已向美国食品药品监督管理局递交新药临床试验申请，计划于2026年启动首次人体临床试验。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1431634.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","IE00BZ08YT58.USD","ADC","BK4231","BK4080","159938","IE00BZ08YS42.EUR","IE00BZ08YR35.GBP","HK0000165453.HKD","BK1191","09939","BK1515","BK1521","BK1589","01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629033331","title":"诺禾致源：4月14日召开业绩说明会，国联民生医药、中金医药参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2629033331","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629033331?lang=zh_cn&edition=full","pubTime":"2026-04-21 18:52","pubTimestamp":1776768740,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年4月17日诺禾致源发布公告称公司于2026年4月14日召开业绩说明会，国联民生医药杨芳、中金医药陈诗雨参与。诺禾致源2026年一季报显示，一季度公司主营收入5.56亿元，同比上升10.84%；归母净利润2945.05万元，同比下降13.06%；扣非净利润2624.51万元，同比上升4.69%；负债率29.4%，投资收益350.08万元，财务费用265.19万元，毛利率41.84%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042100044521.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","01456","BK0221","159938","09939","BK1515","BK1147","BK1564","BK1574","BK1161","688315","601456","BK0276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629174086","title":"天保基建：天津天保医药科技发展有限公司与您提及的公司无业务合作关系","url":"https://stock-news.laohu8.com/highlight/detail?id=2629174086","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629174086?lang=zh_cn&edition=full","pubTime":"2026-04-21 16:09","pubTimestamp":1776758955,"startTime":"0","endTime":"0","summary":"证券之星消息，天保基建(000965)04月21日在投资者关系平台上答复投资者关心的问题。投资者提问：天保生物医药科技有限公司跟GE医疗是否有业务合作，未来是否会推进跟ge资料的业务往来与合作？天保基建回复：您好，天津天保医药科技发展有限公司与您提及的公司无业务合作关系。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042100036145.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0273","BK1161","000965","BK0013","09939","BK1515","BK1574","BK0172","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629703598","title":"金笑非2026年一季度表现，鹏华创新医药混合A基金季度涨幅10.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629703598","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629703598?lang=zh_cn&edition=full","pubTime":"2026-04-21 09:34","pubTimestamp":1776735299,"startTime":"0","endTime":"0","summary":"证券之星消息，截止2026年一季度末，基金经理金笑非旗下共管理9只基金，本季度表现最佳的为鹏华创新医药混合A，季度净值涨10.29%。持有期间的估算收益率为503.76%，持有期间宁德时代在2019年到2022年的年报营业总收入增幅达617.64%。持有期间的估算收益率为91.22%，持有期间百济神州在2024年到2025年的年报归属净利润增幅达129.34%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042100016447.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","BK1574","09939","BK1161","BK1515","160613"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628569761","title":"中国生物制药(01177)：礼新医药于AACR 2026公布MK-2010/LM-299初步临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2628569761","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628569761?lang=zh_cn&edition=full","pubTime":"2026-04-19 18:10","pubTimestamp":1776593401,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药 发布公告，本集团全资附属公司礼新医药科技(上海)有限公司自主研发的创新药MK-2010/LM-299“PD-1/ VEGF双 抗 ”于 2026年美国癌症研究协会年会公布初步临床数据。MK-2010/LM-299是一款在研的四价双特异性抗体，同时靶向程序性细胞死亡蛋白-1 及血管内皮生长因子，其采用IgG-VHH融合结构并具有Fcγ沉默功能。无论是通过联合给药还是双特异性抗体，基于PD-1抑制联合VEGF阻断的治疗策略已在多种晚期实体瘤中显示出临床疗效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430361.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","BK1161","BK1574","09939","BK1521","BK1589","IE00BZ08YT58.USD","IE00BZ08YR35.GBP","BK1515","BK1191","01177","IE00BZ08YS42.EUR","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628021712","title":"批发毛利见底，服务重构破局：万亿医药流通靠零售“回血”？","url":"https://stock-news.laohu8.com/highlight/detail?id=2628021712","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628021712?lang=zh_cn&edition=full","pubTime":"2026-04-17 21:55","pubTimestamp":1776434100,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者唐唯珂医药流通企业悉数交上“年度成绩单”。截至2026年4月，主要医药流通上市公司2025年年报已悉数披露。从行业龙头来看，国药控股在营收端小幅承压的同时，利润端实现逆势修复。2025年公司实现营收5751.68亿元，同比小幅下降1.60%，但归母净利润逆势增长1.50%至71.55亿元，整体经营韧性依然稳固。相比之下，华润医药展现出更为均衡的增长结构。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604173709319635.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604173709319635.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1515","BK1161","09939","BK1574","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628282162","title":"宝莫股份：目前公司产品暂未应用于医药领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2628282162","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628282162?lang=zh_cn&edition=full","pubTime":"2026-04-17 08:39","pubTimestamp":1776386347,"startTime":"0","endTime":"0","summary":"证券之星消息，宝莫股份(002476)04月16日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好，请问公司产品可以衍生用于医药领域？宝莫股份回复：尊敬的投资者您好！公司主要产品涵盖聚丙烯酰胺、稠油降粘剂、表面活性剂等，相关产品主要应用于油气开发领域的三次采油作业、废水处理等场景，目前公司产品暂未应用于医药领域。感谢您对公司的关注与支持！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041700009958.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","BK0004","BK0144","BK0229","BK1161","BK1574","09939","159938","002476","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627829301","title":"同源康医药(02410)自主研发TY-3002单药展现卓越减重疗效，引领下一代口服GLP-1R小分子创新","url":"https://stock-news.laohu8.com/highlight/detail?id=2627829301","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627829301?lang=zh_cn&edition=full","pubTime":"2026-04-16 17:07","pubTimestamp":1776330475,"startTime":"0","endTime":"0","summary":"近日，同源康医药宣布正式提名其自主研发的下一代口服小分子GLP-1R激动剂TY-3002为临床前候选化合物。在反映临床潜力的hGLP-1R饮食诱导肥胖小鼠头对头试验中，TY-3002展现出了优越的减重效果。治疗21天后，TY-3002组小鼠的体重极显著地下降了-31.51%，而同等剂量的Orforglipron组降幅为-22.82%。新一代GLP-1R小分子TY-3002的提名，充分彰显了同源康医药领先的分子设计能力，也为全球下一代口服减重药物领域开启了新的竞争格局。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1429400.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1515","159938","GLP","02410","09939","TY","BK1161","BK4144","BK4590"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627298320","title":"4月16日爱迪特涨10.33%，银河医药混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2627298320","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627298320?lang=zh_cn&edition=full","pubTime":"2026-04-16 16:22","pubTimestamp":1776327742,"startTime":"0","endTime":"0","summary":"证券之星消息，4月16日爱迪特涨10.33%，收盘报76.34元，换手率13.04%，成交量9.39万手，成交额6.89亿元。重仓爱迪特的公募基金请见下表：该股最近90天内共有2家机构给出评级，买入评级2家；过去90天内机构目标均价为98.7。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共3家，其中持有数量最多的公募基金为银河基金的银河医药混合A。银河医药混合A目前规模为4.29亿元，最新净值0.6254，较上一交易日下跌0.27%，近一年上涨26.24%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041600028440.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","BK1161","301580","BK1515","09939","BK1574","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627238145","title":"北京将加快中关村生命科学园三期建设 推动AI+医药、脑机接口等产业发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2627238145","media":"中国新闻网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627238145?lang=zh_cn&edition=full","pubTime":"2026-04-15 21:57","pubTimestamp":1776261468,"startTime":"0","endTime":"0","summary":"中新网北京4月15日电(记者吕少威)今后五年，北京回天地区将提升特色优势产业发展能级，加快中关村生命科学园三期建设，推动AI+医药、脑机接口等产业发展。北京市昌平区副区长柳强在15日举行的一场新闻发布会上提到上述内容。发布会上正式发布《进一步推进回龙观天通苑地区提升发展行动计划(2026—2030年)》。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604153706308848.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604153706308848.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["AIPO","000931","159938","BK0239","BK0178","BK0028","BK1574","09939","BK1161","BK0075","AGIX","BK1515","ARTY","CHAT"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1776973316802,"stockEarnings":[{"period":"1week","weight":-0.0244},{"period":"1month","weight":0.0423},{"period":"3month","weight":-0.0532},{"period":"6month","weight":-0.0921},{"period":"1year","weight":0.0613},{"period":"ytd","weight":-0.0123}],"compareEarnings":[{"period":"1week","weight":0.0093},{"period":"1month","weight":0.0546},{"period":"3month","weight":-0.0104},{"period":"6month","weight":0.0362},{"period":"1year","weight":0.2418},{"period":"ytd","weight":0.0313}],"compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"医药(159938)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供医药(159938)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"医药,159938,医药股票,医药股票老虎,医药股票老虎国际,医药行情,医药股票行情,医药股价,医药股市,医药股票价格,医药股票交易,医药股票购买,医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"医药(159938)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供医药(159938)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}